Literature DB >> 29178534

Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

Markella Konstantinidou1, Tryfon Zarganes-Tzitzikas1, Katarzyna Magiera-Mularz2, Tad A Holak2,3, Alexander Dömling1.   

Abstract

The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  PD-1; PD-L1; antitumor agents; protein structures; protein-protein interactions

Mesh：

Substances：

Year:  2018        PMID： 29178534      PMCID： PMC6280658          DOI： 10.1002/anie.201710407

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


  39 in total

1.  Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.

Authors:  Katarzyna Guzik; Krzysztof M Zak; Przemyslaw Grudnik; Katarzyna Magiera; Bogdan Musielak; Ricarda Törner; Lukasz Skalniak; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  J Med Chem       Date:  2017-06-23       Impact factor: 7.446

2.  A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use.

Authors:  Aasems Jacob; Dileep C Unnikrishnan; Aju Mathew; Braghadheeswar Thyagarajan; Shil Patel
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-17       Impact factor: 4.553

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.

Authors:  David Yin-Wei Lin; Yoshimasa Tanaka; Masashi Iwasaki; Apostolos G Gittis; Hua-Poo Su; Bunzo Mikami; Taku Okazaki; Tasuku Honjo; Nagahiro Minato; David N Garboczi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-14       Impact factor: 11.205

5.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

Authors:  Manish J Butte; Mary E Keir; Theresa B Phamduy; Arlene H Sharpe; Gordon J Freeman
Journal:  Immunity       Date:  2007-07-12       Impact factor: 31.745

6.  Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2.

Authors:  Eszter Lázár-Molnár; Qingrong Yan; Erhu Cao; Udupi Ramagopal; Stanley G Nathenson; Steven C Almo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-18       Impact factor: 11.205

7.  Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.

Authors:  Ju Yeon Lee; Hyun Tae Lee; Woori Shin; Jongseok Chae; Jaemo Choi; Sung Hyun Kim; Heejin Lim; Tae Won Heo; Kyeong Young Park; Yeon Ji Lee; Seong Eon Ryu; Ji Young Son; Jee Un Lee; Yong-Seok Heo
Journal:  Nat Commun       Date:  2016-10-31       Impact factor: 14.919

8.  High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.

Authors:  Shoichiro Horita; Yayoi Nomura; Yumi Sato; Tatsuro Shimamura; So Iwata; Norimichi Nomura
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

9.  Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.

Authors:  Fei Zhang; Hudie Wei; Xiaoxiao Wang; Yu Bai; Pilin Wang; Jiawei Wu; Xiaoyong Jiang; Yugang Wang; Haiyan Cai; Ting Xu; Aiwu Zhou
Journal:  Cell Discov       Date:  2017-03-07       Impact factor: 10.849

10.  Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy.

Authors:  Eszter Lázár-Molnár; Lisa Scandiuzzi; Indranil Basu; Thomas Quinn; Eliezer Sylvestre; Edith Palmieri; Udupi A Ramagopal; Stanley G Nathenson; Chandan Guha; Steven C Almo
Journal:  EBioMedicine       Date:  2017-02-06       Impact factor: 8.143
View more
  22 in total

Review 1.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

2.  In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action.

Authors:  Derek J Blevins; Ronan Hanley; Trevor Bolduc; David A Powell; Michael Gignac; Kayleigh Walker; Mark D Carr; Fraser Hof; Jeremy E Wulff
Journal:  ACS Med Chem Lett       Date:  2019-07-02       Impact factor: 4.345

Review 3.  Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis.

Authors:  Xiaoyun Li; Qin Zeng; Fengjiao Xu; Yuying Jiang; Zhongmei Jiang
Journal:  Mol Divers       Date:  2022-08-10       Impact factor: 3.364

4.  PD-L1 Inhibits T Cell-Induced Cytokines and Hyaluronan Expression via the CD40-CD40L Pathway in Orbital Fibroblasts From Patients With Thyroid Associated Ophthalmopathy.

Authors:  Zhibin Liu; Yao Liu; Mingming Liu; Qingjia Gong; Anjie Shi; Xiuhong Li; Xu Bai; Xiaoyue Guan; Bing Hao; Feila Liu; Xing Zhou; Hongfeng Yuan
Journal:  Front Immunol       Date:  2022-05-10       Impact factor: 8.786

5.  Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs.

Authors:  André E Nel; Kuo-Ching Mei; Yu-Pei Liao; Xiangsheng Liu
Journal:  ACS Nano       Date:  2022-03-29       Impact factor: 18.027

6.  An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy.

Authors:  Jiyoon Bu; Ashita Nair; Mari Iida; Woo-Jin Jeong; Michael J Poellmann; Kara Mudd; Luke J Kubiatowicz; Elizabeth W Liu; Deric L Wheeler; Seungpyo Hong
Journal:  Nano Lett       Date:  2020-06-11       Impact factor: 11.189

Review 7.  A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).

Authors:  Shabnam Shaabani; Harmen P S Huizinga; Roberto Butera; Ariana Kouchi; Katarzyna Guzik; Katarzyna Magiera-Mularz; Tad A Holak; Alexander Dömling
Journal:  Expert Opin Ther Pat       Date:  2018-09-10       Impact factor: 6.674

Review 8.  Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.

Authors:  Heliang Li; Phei Er Saw; Erwei Song
Journal:  Cell Mol Immunol       Date:  2020-04-20       Impact factor: 11.530

9.  Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists.

Authors:  Roberto Butera; Marta Ważyńska; Katarzyna Magiera-Mularz; Jacek Plewka; Bogdan Musielak; Ewa Surmiak; Dominik Sala; Radoslaw Kitel; Marco de Bruyn; Hans W Nijman; Philip H Elsinga; Tad A Holak; Alexander Dömling
Journal:  ACS Med Chem Lett       Date:  2021-04-28       Impact factor: 4.345

10.  PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.

Authors:  Pottayil G Sasikumar; Naremaddepalli S Sudarshan; Srinivas Adurthi; Raghuveer K Ramachandra; Dodderi S Samiulla; Anirudha Lakshminarasimhan; Anuradha Ramanathan; Talapaneni Chandrasekhar; Amit A Dhudashiya; Sumalatha R Talapati; Nagesh Gowda; Sreenivasulareddy Palakolanu; Jiju Mani; Bandi Srinivasrao; David Joseph; Nigam Kumar; Rashmi Nair; Hanudatta S Atreya; Nagaraj Gowda; Murali Ramachandra
Journal:  Commun Biol       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.